Dan Morrison
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$6.7MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $6.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 17, 2020 | NIH | SBIR Phase II Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $491K | 490 BIOTECH INC |
| Jul 15, 2019 | NIH | SBIR Phase II Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $991K | 490 BIOTECH INC |
| Jul 2, 2019 | NIH | SBIR Phase II Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $500K | 490 BIOTECH INC |
| Aug 22, 2018 | NIH | STTR Phase II Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine | $498K | 490 BIOTECH INC |
| Sep 1, 2017 | NIH | STTR Phase II Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine | $496K | 490 BIOTECH INC |
| Sep 1, 2017 | NIH | STTR Phase II Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine | $994K | 490 BIOTECH INC with UNIVERSITY OF TENNESSEE KNOXVILLE |
| Jun 20, 2016 | NIH | SBIR Phase II Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals | $458K | 490 BIOTECH INC |
| Sep 1, 2015 | NIH | SBIR Phase I Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $225K | 490 BIOTECH INC |
| Aug 13, 2015 | NIH | SBIR Phase I Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $225K | 490 BIOTECH INC |
| Aug 1, 2015 | NIH | STTR Phase I Expressing humanized bacterial luciferase in stem cells: Moving beyond firefly luciferase to expand the informational capacity of animal models for regenerative medicine | $150K | 490 BIOTECH INC with UNIVERSITY OF TENNESSEE HEALTH SCI CTR |
| Jul 15, 2015 | NIH | SBIR Phase II Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals | $996K | 490 BIOTECH INC |
| Jul 13, 2015 | NIH | STTR Phase I Expressing humanized bacterial luciferase in stem cells: Moving beyond firefly luciferase to expand the informational capacity of animal models for regenerative medicine | $150K | 490 BIOTECH INC |
| Jul 13, 2015 | NIH | SBIR Phase II Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals | $538K | 490 BIOTECH INC |
Peer ranks
Federal funding#152
Awards as PI#72
Patents#273
Companies
- 490 BIOTECH INCLinked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.